PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Secukinumab - Psoriatic arthritis
PAD Profile : Secukinumab - Psoriatic arthritis
Keywords :
Biologic, NICE, immunosuppressant, interleukin 17A inhibitor, DMARD, bDmard, Disease modulating, Rheumatology
Brand Names Include :
Cosentyx
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Adalimumab
- Ciclosporin
- Etanercept
- Golimumab
- Infliximab
- Sulfasalazine
- Ustekinumab (Psoriasis)
- Certolizumab pegol
- Apremilast
- Ixekizumab
- Tofacitinib
- Methotrexate
- Guselkumab (Psoriasis)
- Upadacitinib
- Risankizumab
Other Indications
- Psoriasis
- Ankylosing spondylitis
- Any paediatric use
- Non-radiographic axial spondyloarthritis
- Hidradenitis suppurativa
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Psoriatic arthritis high cost immunomodulator treatment pathway.
02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriatic Arthritis High Cost immunomodulator Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
05 July 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Certolizumab pegol and Secukinumab as treatment options for treating active psoriatic arthritis after inadequate response to DMARDS in line with NICE and associated treatment pathways.
Prescribing will be by hospital specialists only, in line with NICE TA445 using Blueteq initiation and continuation forms. Certolizumab pegol and Secukinumab will be considered RED on the traffic light system.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs